Literature DB >> 15834443

Effect of galantamine on the human alpha7 neuronal nicotinic acetylcholine receptor, the Torpedo nicotinic acetylcholine receptor and spontaneous cholinergic synaptic activity.

Laura Texidó1, Esteve Ros, Mireia Martín-Satué, Susana López, Jordi Aleu, Jordi Marsal, Carles Solsona.   

Abstract

1. Various types of anticholinesterasic agents have been used to improve the daily activities of Alzheimer's disease patients. It was recently demonstrated that Galantamine, described as a molecule with anticholinesterasic properties, is also an allosteric enhancer of human alpha4beta2 neuronal nicotinic receptor activity. We explored its effect on the human alpha7 neuronal nicotinic acetylcholine receptor (nAChR) expressed in Xenopus oocytes. 2. Galantamine, at a concentration of 0.1 microM, increased the amplitude of acetylcholine (ACh)-induced ion currents in the human alpha7 nAChR expressed in Xenopus oocytes, but caused inhibition at higher concentrations. The maximum effect of galantamine, an increase of 22% in the amplitude of ACh-induced currents, was observed at a concentration of 250 microM Ach. 3. The same enhancing effect was obtained in oocytes transplanted with Torpedo nicotinic acetylcholine receptor (AChR) isolated from the electric organ, but in this case the optimal concentration of galantamine was 1 microM. In this case, the maximum effect of galantamine, an increase of 35% in the amplitude of ACh-induced currents, occurred at a concentration of 50 microM ACh. 4. Galantamine affects not only the activity of post-synaptic receptors but also the activity of nerve terminals. At a concentration of 1 microM, quantal spontaneous events, recorded in a cholinergic synapse, increased their amplitude, an effect which was independent of the anticholinesterasic activity associated with this compound. The anticholinesterasic effect was recorded in preparations treated with a galantamine concentration of 10 microM. 5. In conclusion, our results show that galantamine enhances human alpha7 neuronal nicotinic ACh receptor activity. It also enhances muscular AChRs and the size of spontaneous cholinergic synaptic events. However, only a very narrow range of galantamine concentrations can be used for enhancing effects.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15834443      PMCID: PMC1576175          DOI: 10.1038/sj.bjp.0706221

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  40 in total

1.  lynx1, an endogenous toxin-like modulator of nicotinic acetylcholine receptors in the mammalian CNS.

Authors:  J M Miwa; I Ibanez-Tallon; G W Crabtree; R Sánchez; A Sali; L W Role; N Heintz
Journal:  Neuron       Date:  1999-05       Impact factor: 17.173

2.  Solid-phase extraction and reversed-phase high-performance liquid chromatography of the five major alkaloids in Narcissus confusus.

Authors:  Susana López; Jaume Bastida; Francesc Viladomat; Carles Codina
Journal:  Phytochem Anal       Date:  2002 Nov-Dec       Impact factor: 3.373

3.  Effects of bis(7)-tacrine on spontaneous synaptic activity and on the nicotinic ACh receptor of Torpedo electric organ.

Authors:  E Ros; J Aleu; I Gomez de Aranda; C Cantí; Y P Pang; J Marsal; C Solsona
Journal:  J Neurophysiol       Date:  2001-07       Impact factor: 2.714

Review 4.  Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease.

Authors:  A Maelicke; M Samochocki; R Jostock; A Fehrenbacher; J Ludwig; E X Albuquerque; M Zerlin
Journal:  Biol Psychiatry       Date:  2001-02-01       Impact factor: 13.382

5.  Inositol trisphosphate and cyclic adenosine diphosphate-ribose increase quantal transmitter release at frog motor nerve terminals: possible involvement of smooth endoplasmic reticulum.

Authors:  E Brailoiu; M D Miyamoto
Journal:  Neuroscience       Date:  2000       Impact factor: 3.590

Review 6.  Unconventional ligands and modulators of nicotinic receptors.

Authors:  Edna F R Pereira; Corey Hilmas; Mariton D Santos; Manickavasagom Alkondon; Alfred Maelicke; Edson X Albuquerque
Journal:  J Neurobiol       Date:  2002-12

7.  The pharmacology of novel acetylcholinesterase inhibitors, (+/-)-huprines Y and X, on the Torpedo electric organ.

Authors:  E Ros; J Aleu; I Gómez de Aranda; D Muñoz-Torrero; P Camps; A Badia; J Marsal; C Solsona
Journal:  Eur J Pharmacol       Date:  2001-06-08       Impact factor: 4.432

Review 8.  Alzheimer's disease and the basal forebrain cholinergic system: relations to beta-amyloid peptides, cognition, and treatment strategies.

Authors:  Daniel S Auld; Tom J Kornecook; Stéphane Bastianetto; Rémi Quirion
Journal:  Prog Neurobiol       Date:  2002-10       Impact factor: 11.685

9.  The nicotinic allosteric potentiating ligand galantamine facilitates synaptic transmission in the mammalian central nervous system.

Authors:  Máriton D Santos; Manickavasagom Alkondon; Edna F R Pereira; Yasco Aracava; Howard M Eisenberg; Alfred Maelicke; Edson X Albuquerque
Journal:  Mol Pharmacol       Date:  2002-05       Impact factor: 4.436

10.  Galantamine: effect on nicotinic receptor binding, acetylcholinesterase inhibition, and learning.

Authors:  D S Woodruff-Pak; R W Vogel; G L Wenk
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-06       Impact factor: 11.205

View more
  15 in total

Review 1.  The therapeutic potential of α7 nicotinic acetylcholine receptor (α7 nAChR) agonists for the treatment of the cognitive deficits associated with schizophrenia.

Authors:  Corinne Beinat; Samuel D Banister; Marco Herrera; Vivian Law; Michael Kassiou
Journal:  CNS Drugs       Date:  2015-07       Impact factor: 5.749

2.  Nootropic alpha7 nicotinic receptor allosteric modulator derived from GABAA receptor modulators.

Authors:  Herman J Ng; Edward R Whittemore; Minhtam B Tran; Derk J Hogenkamp; Ron S Broide; Timothy B Johnstone; Lijun Zheng; Karen E Stevens; Kelvin W Gee
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-30       Impact factor: 11.205

3.  Galantamine is not a positive allosteric modulator of human α4β2 or α7 nicotinic acetylcholine receptors.

Authors:  Natalia M Kowal; Philip K Ahring; Vivian W Y Liao; Dinesh C Indurti; Benjamin S Harvey; Susan M O'Connor; Mary Chebib; Elin S Olafsdottir; Thomas Balle
Journal:  Br J Pharmacol       Date:  2018-06-07       Impact factor: 8.739

Review 4.  Acetylcholine nicotinic receptor subtypes in chromaffin cells.

Authors:  Manuel Criado
Journal:  Pflugers Arch       Date:  2017-08-08       Impact factor: 3.657

Review 5.  [Therapy of cognitive deficits in schizophrenia with acetylcholinesterase inhibitors. A systematic overview].

Authors:  B Voss; R Thienel; S Leucht; T Kircher
Journal:  Nervenarzt       Date:  2008-01       Impact factor: 1.214

Review 6.  Therapeutic potential of α7 nicotinic acetylcholine receptor agonists to combat obesity, diabetes, and inflammation.

Authors:  Han Xie; Natesh Yepuri; Qinghe Meng; Ravi Dhawan; Colin A Leech; Oleg G Chepurny; George G Holz; Robert N Cooney
Journal:  Rev Endocr Metab Disord       Date:  2020-08-26       Impact factor: 6.514

7.  Physostigmine and galanthamine bind in the presence of agonist at the canonical and noncanonical subunit interfaces of a nicotinic acetylcholine receptor.

Authors:  Ayman K Hamouda; Tilia Kimm; Jonathan B Cohen
Journal:  J Neurosci       Date:  2013-01-09       Impact factor: 6.167

Review 8.  Structural answers and persistent questions about how nicotinic receptors work.

Authors:  Gregg B Wells
Journal:  Front Biosci       Date:  2008-05-01

9.  Human α4β2 nicotinic acetylcholine receptor as a novel target of oligomeric α-synuclein.

Authors:  Qiang Liu; Sharareh Emadi; Jian-Xin Shen; Michael R Sierks; Jie Wu
Journal:  PLoS One       Date:  2013-02-20       Impact factor: 3.240

10.  CHRNA7 polymorphisms and response to cholinesterase inhibitors in Alzheimer's disease.

Authors:  Pei-Hsuan Weng; Jen-Hau Chen; Ta-Fu Chen; Yu Sun; Li-Li Wen; Ping-Keung Yip; Yi-Min Chu; Yen-Ching Chen
Journal:  PLoS One       Date:  2013-12-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.